Debiopharm Completes Enrollment for First-Ever Yearly Injectable Triptorelin Formulation in Pediatric Central Precocious Puberty Trial
核心洞察
Debiopharm (搜索) successfully completed patient enrollment in its Phase III LIBELULA trial evaluating Debio 4326, a unique 12-month extended-release triptorelin formulation for central precocious puberty (搜索) treatment.
The trial aims to reduce injection frequency from current options of 1-, 3-, or 6-month intervals to once yearly, potentially decreasing treatment burden for children and families.
Central precocious puberty (搜索) affects approximately 1 in 5,000-10,000 Caucasian children and can lead to serious long-term health complications including metabolic disorders and increased cancer risk.
Debiopharm (搜索) announced the successful completion of patient enrollment in its Phase III LIBELULA trial (NCT06129539), marking a significant milestone in developing the first-ever yearly injectable formulation of triptorelin for treating central precocious puberty (搜索) (CPP (搜索)) in children. The open-label, single-arm, multi-center study evaluates Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation designed to reduce treatment burden for pediatric patients.
Revolutionary Treatment Approach
The LIBELULA trial leverages Debiopharm (搜索)'s proprietary DEBIO SPHERE Long-Acting Release Platform technology to potentially transform CPP (搜索) treatment by extending injection intervals from current options of 1-, 3-, or 6-month formulations to once yearly. This advancement addresses a critical unmet need in pediatric endocrinology, where frequent injections create significant logistical and emotional stress for families.
"We acknowledge that frequent injections can be burdensome for both children and their families. Advancing extended-release formulations to market is essential for enhancing patient quality of life," stated Cédric Sager, Chief Executive Officer at Debiopharm (搜索) Research & Manufacturing.
Clinical Significance and Patient Impact
Central precocious puberty (搜索) occurs at an unusually early age, before 8 years in girls and before 9 years in boys, characterized by premature development of secondary sexual characteristics and accelerated growth. The condition affects approximately 1 in 5,000-10,000 Caucasian children, with higher prevalence in girls than boys globally.
The long-term health implications of untreated CPP (搜索) are substantial, including increased risk of metabolic complications such as type 2 diabetes (搜索), weight gain, obesity (搜索), and cardiovascular disease (搜索). Additionally, early puberty is associated with depression (搜索), premature death, increased breast cancer (搜索) risk in women, and potentially higher prostate cancer (搜索) risk in men.
Dr. Karen Klein, Clinical Investigator and Interim Chief of Endocrinology/Diabetes Division at Rady Children's Hospital (搜索) – San Diego, emphasized the clinical importance: "Reaching full enrollment for the LIBELULA trial brings us closer to a significant advancement for children burdened by Central Precocious Puberty (搜索). While existing treatments are very effective, the promise of a reliable, once-a-year injectable formulation like Debio 4326 simplifies the treatment schedule to reduce the logistical and emotional stress on families and children."
Study Design and Global Reach
The Phase III trial is being conducted across the United States, Argentina, Brazil, Chile, and Mexico, demonstrating Debiopharm (搜索)'s commitment to addressing this pediatric condition across diverse populations. The study aims to assess the efficacy, safety, and pharmacokinetics of Debio 4326 while maintaining the established therapeutic benefits of triptorelin.
Since the early 1980s, Gonadotropin-Releasing Hormone agonists (GnRHa) such as triptorelin have been the standard of care for CPP (搜索) treatment, aiming to preserve adult height and prevent social and psychological difficulties. Current treatment options include various extended-release GnRHa formulations ranging from monthly injections to subcutaneous implants for annual use, though the latter requires yearly surgical positioning.
Technology and Manufacturing
Debio 4326 is manufactured by Debiopharm (搜索) Research & Manufacturing in Martigny, Switzerland, utilizing the company's expertise in developing extended-release formulations. Based on favorable efficacy and safety data with different triptorelin formulations (1-, 3-, and 6-month), Debio 4326 aims to preserve efficacy while providing increased comfort, ensuring long-term compliance, and reducing stress for children and their parents.
Debiopharm (搜索) is actively engaged in partnering activities for the future registration and commercialization of Debio 4326 in the United States, positioning the therapy for potential market entry pending successful trial results.